Metronomic Chemotherapy: Direct Targeting of Cancer Cells after all?
Metronomic Chemotherapy: Direct Targeting of Cancer Cells after all?
复制标题
DOI：
10.1016/j.trecan.2017.03.011
复制
发表时间：
2017-05-01
期刊：
影响因子：
18.4
通讯作者：
Pasquier, Eddy
中科院分区：
文献类型：
--
作者：
Andre, Nicolas;Tsai, Kelvin;Pasquier, Eddy
节拍化疗（MC）最初被描述为一种抗血管生成治疗超过15年前。在过去的几年里，更多的数据强调了MC对微环境的影响，而不仅仅是血管生成，最重要的是，对免疫系统的潜在影响。在这里，我们回顾和重新评估MC可能能够直接杀死癌细胞的事实。虽然长期被忽视，但这个问题在根本上和临床上都至关重要，特别是在考虑未来与免疫疗法的关系时。
Metronomic chemotherapy (MC) was initially described as an antiangiogenic therapy more than 15 years ago. Over the past few years, additional data have highlighted the impact of MC on the microenvironment beyond angiogenesis, with, most importantly, a potential impact on the immune system. Here, we review and reappraise the fact that MC might be able to directly kill cancer cells. Although long neglected, this question is of critical importance both fundamentally and clinically, especially when considering future associations with immunotherapies.